CDR most commonly stands for Clinical Dementia Rating, a standardized scale doctors and researchers use to measure the severity of Alzheimer’s disease and related dementias. It rates cognitive and functional decline on a 0-to-3 scale, where 0 means no dementia and 3 means severe dementia. The CDR is one of the most widely used tools in dementia research and clinical practice, with pooled sensitivity of 87% for detecting dementia and 93% for detecting mild cognitive impairment.
What the CDR Measures
The CDR evaluates six areas of daily cognitive and functional ability: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. Each domain is scored independently, then combined into an overall rating. The first three domains are assessed through direct evaluation of the person being tested as well as input from someone who knows them well, like a spouse or adult child. The remaining three rely entirely on that informant’s observations of how the person functions day to day.
This dual approach, combining clinical assessment with real-world input from a caregiver, is a key strength of the CDR. A person might perform reasonably well in a structured office visit but struggle significantly at home, and the informant interview captures that gap.
How CDR Scores Map to Dementia Stages
Each of the six domains receives a box score ranging from 0 (normal) to 3 (severe impairment). These individual ratings are then used to assign a global CDR score:
- CDR 0 (None): No memory loss, fully oriented, handles problems and daily activities independently.
- CDR 0.5 (Questionable): Consistent slight forgetfulness, minor difficulty with time relationships, slight impairment in problem-solving. This stage often corresponds to what clinicians call mild cognitive impairment.
- CDR 1 (Mild): Moderate memory loss that interferes with everyday activities, difficulty with time and place, unable to function independently in community activities though the person may still appear normal to casual observers.
- CDR 2 (Moderate): Severe memory loss with only deeply learned material retained, frequently disoriented to time and often to place, severely impaired judgment, no independent function outside the home.
- CDR 3 (Severe): Only fragments of memory remain, oriented to person only, unable to make judgments or solve problems, requires substantial help with personal care.
The memory domain carries the most weight in the global score. If a person’s memory rating differs from the other five domains, a specific algorithm determines which value takes priority. In practice, memory impairment is typically the earliest and most prominent feature the CDR captures.
The Sum of Boxes Score
Researchers and clinical trial designers often prefer a variation called the CDR Sum of Boxes (CDR-SB). Instead of collapsing everything into a single 0-to-3 number, the CDR-SB adds up the individual box scores from all six domains, producing a score from 0 to 18. This wider range makes it much more sensitive to small changes over time.
The global CDR score can stay at 1 for years even as a person gradually worsens within that stage. The CDR-SB, by contrast, can detect that progression because it captures incremental shifts across multiple domains. It’s also simpler to calculate than the global score, which requires a specific algorithm that can introduce errors. For these reasons, the CDR-SB has become the primary outcome measure in many Alzheimer’s drug trials, where detecting even modest slowing of decline is critical.
How the Assessment Works
The CDR is administered through semi-structured interviews, one with the person being evaluated and one with a reliable informant. The clinician asks open-ended questions designed to reveal how the person handles everyday situations: managing finances, remembering recent events, navigating familiar routes, maintaining hobbies, and caring for themselves. The interviews are conversational rather than quiz-like, which helps capture a more naturalistic picture of function.
The entire process typically takes 30 to 60 minutes. It requires a trained rater, usually a neurologist, psychiatrist, or neuropsychologist, who scores each domain based on the combined information from both interviews. The CDR was originally developed at Washington University in St. Louis in the early 1980s for a study of mild Alzheimer’s disease, and the Knight Alzheimer Disease Research Center there still maintains the official training and certification program.
How Accurate the CDR Is
A large meta-analysis of diagnostic accuracy studies found that the global CDR score detects mild cognitive impairment with 93% sensitivity and 97% specificity. For dementia, sensitivity is 87% with specificity reaching 99%. These are strong numbers, meaning the CDR rarely misses true cases and almost never flags healthy people as impaired.
The CDR-SB performs comparably for sensitivity but is slightly less specific (94% vs. 99%) when distinguishing dementia from normal aging. This tradeoff is generally acceptable in research settings, where catching every case matters more than avoiding false positives. In clinical settings, the global score’s higher specificity makes it useful for confirming a diagnosis.
CDR in Immunology
In a completely different context, CDR also stands for complementarity-determining regions, the parts of an antibody that physically contact and bind to a target molecule like a virus or bacteria. Each antibody has six CDRs split between its two protein chains, and the specific sequence of amino acids in these regions determines what the antibody recognizes. One CDR in particular, called H3, sits at the center of antigen recognition and is the most diverse, allowing otherwise identical antibodies to distinguish between very different targets. If you searched “CDR” in the context of immunology or molecular biology, this is likely what you were looking for.